Short-interval HPV retesting showed promise for identifying high-risk cervical neoplasia in HPV-positive patients. A positive repeat HPV test at 2 months had 82-88% sensitivity for high-grade cervical ...

An experimental therapeutic human papillomavirus (HPV) vaccine showed promise in inducing regression of precancerous cervical lesions as well as viral clearance in patients with cervical ...

In a recent study published in the Journal of the National Cancer Institute, researchers assessed a novel human papillomavirus (HPV) and host deoxyribonucleic acid (DNA) methylation score for ...

Both complete and incomplete vaccination in individuals were associated with a significantly lower detection rate of high-risk HPV 16/18 and 16/18/31/33/45 in CIN2 compared with no vaccination.

In a recent study published in BMJ, researchers in England assessed the efficiency of the human papillomavirus (HPV) vaccination program in reducing the prevalence of cervical cancers and grade 3 ...

For individuals younger than 25 years, the incidence of cervical intraepithelial neoplasia (CIN) decreased continuously from 2007 through 2020, according to a research letter published online July 25 ...

Cervical cancer is one of the most common cancers in women, with approximately 660,000 new cases and 350,000 deaths worldwide in 2022 alone. Almost all cases are linked to high-risk human ...

A new urine test might help doctors more easily screen for cervical cancer, researchers report. The test looks for proteins generated by a type of cancer-causing human papillomavirus, HPV 16. HPV ...